Tick-borne Encephalitis and Borrelial Antibodies in Serum

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · May 17, 2019

Keywords

ClinConnect Summary

This clinical trial is studying tick-borne encephalitis, a serious illness caused by a virus transmitted through the bite of infected ticks. The researchers want to understand whether patients who have tick-borne encephalitis and also show signs of Lyme disease antibodies in their blood benefit from antibiotic treatment. They believe that treating these patients with antibiotics may not be necessary and could lead to unwanted side effects, such as reactions to the medication and issues related to antibiotic resistance.

To be eligible for the trial, participants need to be at least 18 years old and show symptoms that suggest they have tick-borne encephalitis, along with specific test results indicating tick-borne encephalitis and Lyme disease antibodies in their blood. Participants will undergo tests to confirm their condition and may receive close monitoring throughout the study. This trial is currently recruiting participants and aims to provide valuable insights into the best treatment approaches for tick-borne illnesses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • clinical picture compatible with tick-borne encephalitis,
• • clear cerebrospinal fluid,
• • cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid \>5 x 106/)L,
• • positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against tick-borne encephalitis virus,
• • positive serum IgG antibodies against Lyme borreliae.
• Exclusion Criteria:
• • isolation of B.burgdorferi sensu lato from cerebrospinal fluid,
• • positive intrathecal borrelial antibody production index,
• • seroconversion of borrelial IgG antibodies,
• • presence of erythema migrans and/or borrelial lymphocytoma in the last month,
• • Bannwarth syndrome.